Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
| Autor: | Yukihisa Hatakeyama, Yoshikazu Kotani, Suya Hori, Kazuyuki Kobayashi, Tatsuya Nagano, Yasuhiro Funada, Yoshihiro Nishimura, Daisuke Kasai, Daisuke Tamura, Masahiro Katsurada |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Case Report Pharmacology Gastroenterology Transaminase Gefitinib Internal medicine medicine heterocyclic compounds Epidermal growth factor receptor skin and connective tissue diseases neoplasms lcsh:RC705-779 Lung biology business.industry Cancer lcsh:Diseases of the respiratory system medicine.disease Discontinuation respiratory tract diseases medicine.anatomical_structure biology.protein Adenocarcinoma Erlotinib business medicine.drug |
| Zdroj: | Case Reports in Pulmonology Case Reports in Pulmonology, Vol 2011 (2011) |
| ISSN: | 2090-6854 2090-6846 |
| Popis: | A 73-year-old Japanese man was histologically diagnosed with lung adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor. The patient was treated with gefitinib for 6 weeks until he developed substantially elevated hepatic enzyme levels that resulted in the discontinuation of gefitinib. Gefitinib was reintroduced with an intermittent treatment schedule after the transaminase levels normalized, but the patient's enzyme levels rose again, and the cancer progressed. Gefitinib was eventually replaced with erlotinib. There was stable disease for 7 weeks without any signs of liver toxicity. Thus, erlotinib may be a beneficial and well-tolerated treatment option for patients with gefitinib-related hepatotoxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text